A phase III, multicenter, randomized, blind, controlled trial for efficacy and safety of tazarotene and betamethasone dipropionate cream in the treatment of subjects with psoriasis vulgaris

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900024450

Enrollment

Unknown

Registered

2019-07-12

Start date

2010-03-15

Completion date

Unknown

Last updated

2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis vulgaris

Interventions

Group 1:0.05% betamethasone dipropionate cream (Applied twice daily in the morning and evening)

Group 2:Placebo(once in the morning) +0.05% tazarotene gel (once in the evening)

Group 3:Placebo (once in the morning) + Tazarotene and Betamethasone Dipropionate Cream (once in the evening)

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Diagnosis of chronic plaque psoriasis; (2) Psoriasis affecting <20% of the body surface area; (3) Aged between 18 and 65 years, either sex; (4) Subjects having understood and signed a written informed consent form prior to any study related procedures being carried out.

Exclusion criteria

Exclusion criteria: (1) Treatment with tretinoin drugs within 16 weeks, anti-tumor drugs within 6 weeks, topical or phototherapy within 4 weeks prior to randomization; (2) History of allergy to tretinoin drugs or any component of the study drug; (3) Patients with systemic diseases such as endocrine diseases, mental diseases, blood diseases, liver and kidney diseases, cardiovascular and cerebrovascular diseases, and immune dysfunction; (4) Females who are pregnant, wishing to become pregnant in the next 3 months, or are breast-feeding. (5) Psoriasis affecting more than 20% of body surface area; (6) Diagnosis of psoriasis other than the type of chronic plaque psoriasis; (7) Treatment with systemic anti-psoriasis medications during the study period; (8) Participation in any other clinical study 3 months prior to randomization; (9) Patients excluded by the investigator; (10) Planned initiation of, or changes in, concomitant medication that may affect the observation and judgment of the study; (11) Staff members directly involved in the study.

Design outcomes

Primary

Measure	Time frame
Decline rate of PASI;	—

Secondary

Measure	Time frame
Target lesion recurrence rate;	—

Countries

China

Contacts

Public ContactSun Jianfang

Chinese Academy of Medical Sciences & Hospital for Skin Diseases

Fangmin5758@yahoo.com.cn+86 13951984310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026